Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,106
Employees15,106
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,106
Employees15,106

REGN Key Statistics

Market cap
83.88B
Market cap83.88B
Price-Earnings ratio
18.27
Price-Earnings ratio18.27
Dividend yield
0.46%
Dividend yield0.46%
Average volume
575.76K
Average volume575.76K
High today
$807.83
High today$807.83
Low today
$780.10
Low today$780.10
Open price
$786.18
Open price$786.18
Volume
494.82K
Volume494.82K
52 Week high
$807.83
52 Week high$807.83
52 Week low
$476.49
52 Week low$476.49

Stock Snapshot

Regeneron(REGN) stock is priced at $798.08, giving the company a market capitalization of 83.88B. It carries a P/E multiple of 18.27 and pays a dividend yield of 46.1%.

On 2026-01-07, Regeneron(REGN) stock moved within a range of $780.10 to $807.83. With shares now at $798.08, the stock is trading +2.3% above its intraday low and -1.2% below the session's peak.

Trading activity shows a volume of 494.82K, compared to an average daily volume of 575.76K.

The stock's 52-week range extends from a low of $476.49 to a high of $807.83.

The stock's 52-week range extends from a low of $476.49 to a high of $807.83.

REGN News

TipRanks 6h
Regeneron upgraded to Buy from Underperform at BofA

BofA upgraded Regeneron (REGN) to Buy from Underperform with a price target of $860, up from $627. Claim 70% Off TipRanks Premium Published first on TheFly –...

TipRanks 2d
Sanofi and Regeneron Expand Dupilumab’s Real-World Footprint in Chronic Urticaria

Regeneron Pharmaceuticals (REGN), Sanofi SA (SNY) announced an update on their ongoing clinical study. Claim 70% Off TipRanks This Holiday Season Study Overvi...

Nasdaq 2d
Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026

The medical sector is one of the major adopters of artificial intelligence (AI), which is currently being used to synthesize new compounds for drugs and create...

Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026

Analyst ratings

70%

of 30 ratings
Buy
70%
Hold
30%
Sell
0%

More REGN News

Simply Wall St 2d
Assessing Regeneron Pharmaceuticals Valuation After Recent Share Price Momentum

Regeneron Pharmaceuticals (REGN) has drawn investor attention after its recent share price move, with the stock closing at $776.31. That shift is prompting fres...

Assessing Regeneron Pharmaceuticals Valuation After Recent Share Price Momentum

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.